Beckley Psytech raises £3m to develop ground-breaking psychedelic medicines
July 9th, 2020
Beckley Psytech, the psychedelic medicine company, has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases. Investors in the round include prominent British businessmen Jim Mellon and Richard Reed, co-founder of Innocent Drinks.
The Beckley Psytech team comprises talent from the psychedelic and pharmaceutical fields. Co-founded by world-renowned leader in psychedelic research Lady Amanda Feilding and CEO Cosmo Feilding Mellen, the executive team also includes Marc Wayne as Chairman of Board and Dr Steve Wooding, Chief Scientific Officer. Wayne is a pioneer of the Canadian medical cannabis industry and Wooding is the former head of global commercial strategy for Janssen, Johnson and Johnson’s pharmaceutical division.
The prevalence of mental health and central nervous system (CNS) disorders is growing year on year, with roughly 1 in 4 people1 around the world affected by these conditions in their lifetimes, and with mental health set to become the biggest disease burden globally, potentially exacerbated by the current pandemic. Existing treatments are often sub- optimal and may cause treatment limiting side-effects 2, however currently controlled “psychedelic” drugs such as psilocybin and MDMA have shown early promise in the treatment of debilitating mental and neurological disorders.
Beckley Psytech is developing a drug pipeline of psychedelic medicines with significant commercial potential to address this unmet clinical need. The company is borne out of a strategic partnership with the Beckley Foundation, a renowned non-profit NGO with a 20 year track record of advancing scientific research into psychedelic medicine. The Foundation initiated the first ever brain-imaging study of psilocybin, the active ingredient in ‘magic mushrooms’, and, subsequently, the first clinical trial of the drug for treatment
resistant depression (TRD) at Imperial College London. In addition to its own pipeline, Beckley Psytech will have first opportunity to support the commercialisation of the Foundation’s intellectual property and will allocate a share of its revenues to fund the Foundation’s ongoing research as part of its commitment to corporate social responsibility.
Beckley Psytech will use the Series A funding to advance its lead programme exploring the use of synthetic 5-MeO-DMT, a unique psychedelic agent with a short duration of action, in the treatment of neuropsychiatric diseases. The funding will help with scaling up resources to develop novel pharmaceutical formulations and delivery methods for synthetic 5-MeO-DMT, as well as to progress preclinical and clinical trials.
Cosmo Feilding Mellen, co-founder and CEO, Beckley Psytech, says: “Our diverse and experienced leadership team is perfectly positioned to deliver on our mission of making effective and safe psychedelic medicines available to patients in need and integrating these treatments into mainstream medical practice.
“This investment comes at an exciting time as we look to build on our progress into an area with transformational potential for society. The capital will enable us to put more resources into exploring 5-MeO-DMT and creating a viable pathway for it to enter the market, as well as the exploration of other agents.”
Dr Steve Wooding, Chief Scientific Officer, Beckley Psytech, says: “There is a significant market opportunity for psychedelic medicines and we are developing a pipeline of assets which we hope will deliver transformative care to patients.
“Beckley Psytech will capitalise on its unique medical, scientific and commercial connections to develop under-researched psychedelic agents into fully licensed medicines that could significantly improve quality of life for patients suffering from intractable, chronic mental and neurological conditions.”
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.